Axial Spondyloarthritis Market By Treatment Type (TNF Inhibitors, IL-17 Inhibitors, JAK Inhibitors, NSAIDs, Conventional DMARDs, Other Therapies); By Disease Type (Radiographic Axial Spondyloarthritis, Non-Radiographic Axial Spondyloarthritis); By Route of Administration (Injectable, Oral, Intravenous); By End User (Hospitals, Rheumatology Clinics, Specialty Clinics, Homecare Settings); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Axial Spondyloarthritis Market: Earlier Diagnosis Expands Treatment Demand While Biosimilars Reset the Revenue Model

The Global Axial Spondyloarthritis (AxSpA) Market will experience consistent growth at a CAGR of 7.4%, increasing from USD 5.58 billion in 2025 to USD 9.21 billion by 2032, according to Strategic Market Research. 

 

The market is commercially defined by recurring pharmacotherapy, specialist diagnosis, reimbursement approval, treatment persistence, and switching between targeted drug classes. The 2025 British Society for Rheumatology guideline positions TNF, IL-17, and JAK inhibitors for active disease that remains inadequately controlled after conventional management. Continued treatment depends on maintained response, while intolerance, inadequate response, or loss of efficacy moves patients between products and mechanisms.

 

Targeted biologics are estimated to account for approximately 68% of axial spondyloarthritis treatment expenditure in 2025, equivalent to about USD 3.79 billion of the total market. If this share remains broadly stable, biologic revenue would rise to approximately USD 6.26 billion by 2032, adding USD 2.47 billion at a 7.4% CAGR. The remaining 32%, or about USD 1.79 billion in 2025, is distributed across oral targeted medicines, conventional pharmacotherapy, rehabilitation, and other supporting treatment pathways. This mix explains why biologic initiation, persistence, biosimilar pricing, and class switching have greater influence on market value than procedure volumes.

 

The Addressable Population Is Narrower Than the Epidemiological Burden

A U.S. NHANES analysis estimated spondyloarthritis prevalence among adults aged 20–69 at 0.9% under Amor criteria and 1.4% under European Spondyloarthropathy Study Group criteria. These rates establish the broad disease pool, while the revenue-generating population is narrowed by diagnosis, active-disease status, objective inflammation, specialist access, and payer eligibility.

Claims data provide a more commercially relevant measure. Between 2006 and 2014, annual coded axial spondyloarthritis prevalence increased from 4.39 to 6.52 per 10,000 Medicare beneficiaries and from 1.33 to 2.21 per 10,000 MarketScan members. This represented 1.5-fold growth in Medicare and 1.7-fold growth in commercially insured patients. Greater clinical awareness, MRI use, coding recognition, and rheumatology referral expanded the identifiable treatment pool even without an equivalent increase in underlying incidence.

England reported recorded axial spondyloarthritis prevalence of 0.113% in 2020 through the CPRD Aurum database. The distinction between epidemiological prevalence and recorded disease is commercially important: market growth is created when previously unrecognized patients enter specialist care and qualify for recurring treatment, not when broad prevalence estimates rise on paper.

 

Specialist Diagnosis Produces Rapid Treatment Conversion

A U.S. electronic health record study covering 2,641 newly diagnosed patients between 2016 and 2022 found that 87% initiated medication within 12 months and 73% started within one month. Biologics were used as first-line therapy, alone or in combination, in 47% of patients, showing that specialist diagnosis is a high-value conversion point rather than a prolonged observation stage. Approximately 52% received at least one patient-reported outcome assessment, but only 38% met the recommended frequency of two or more assessments during the first year.

Real-world claims from 5,970 adults starting biologic or targeted synthetic therapy provide a clearer view of class share. TNF inhibitors accounted for 76.7% of index targeted treatments, confirming their dominant utilization position despite growing IL-17 and JAK competition. Persistence declined from 67.8% at six months to 57.7% at nine months and 54.4% at 12 months. Almost half of patients therefore discontinued, switched, or interrupted a given targeted treatment within one year, making retention as important as initiation for manufacturer revenue.

Outcome monitoring remains a commercial bottleneck. Weak documentation can delay switching, undermine continuation authorization, and reduce the evidence available to differentiate brands in payer negotiations. Digital outcome capture, specialty-pharmacy adherence programs, and rheumatology workflow platforms can improve the conversion of initial prescriptions into recurring treatment revenue.

 

MRI Moves Treatment Earlier but Does Not Guarantee Reimbursement

MRI enables inflammatory sacroiliac-joint changes to be identified before structural damage appears on conventional radiographs. This expands recognition of non-radiographic axial spondyloarthritis and moves treatment evaluation earlier in the patient lifecycle, potentially increasing cumulative treated patient-years.

The commercial conversion remains selective. MRI findings associated with sacroiliitis have also been reported in 57.1% of postpartum women, 16.7% of runners, and 25.5% of healthy individuals when a relatively low imaging threshold was applied. Payers and rheumatologists therefore assess imaging alongside symptoms, C-reactive protein, structural findings, and specialist interpretation rather than treating bone-marrow oedema as a standalone qualification for premium therapy.

Regulatory labels and coverage policies for non-radiographic disease commonly require objective inflammation demonstrated through elevated CRP, MRI findings, or both. Earlier imaging supports market expansion only when it produces a defensible diagnosis and reimbursable treatment decision. MRI capacity without specialist interpretation can increase referrals and testing activity without generating an equivalent rise in paid biologic use.

 

Radiographic Disease Protects Volume While Non-Radiographic Disease Extends Market Duration

Radiographic axial spondyloarthritis remains the mature treatment-volume segment because visible structural damage, established diagnostic pathways, and longer reimbursement history support broad targeted-therapy use. MarketScan data showed TNF-inhibitor utilization among identified ankylosing spondylitis patients rising from 51.7% in 2006 to 65.7% in 2014, while prescription NSAID use declined from 63.5% to 55.7%.

The segment retains high patient volume but faces the strongest net-price pressure. Multiple originators, biosimilars, preferred formularies, and established switching protocols reduce dependence on any single product. Revenue growth therefore trails prescription growth when payer discounts and biosimilar substitution lower value per treated patient.

Non-radiographic axial spondyloarthritis is the more selective expansion segment because qualifying patients can begin targeted treatment before irreversible radiographic damage. Germany’s G-BA referenced approximately 19,500 adults within an assessed active non-radiographic population after previous biologic treatment. This reimbursement-defined pool illustrates how objective inflammation and treatment history reduce addressability relative to broad prevalence.

Non-radiographic disease can contribute disproportionately to future revenue duration even without holding the largest current share. Earlier identification creates more potential treatment years, but the segment’s realized growth depends on MRI access, interpretation quality, specialist capacity, prior-treatment requirements, and payer approval.

 

TNF Inhibitors Retain the Gateway Position but Lose Pricing Power

TNF inhibitors remain the largest targeted-treatment subsegment by utilization, represented by their 76.7% share of index biologic and targeted synthetic starts in recent U.S. claims. Their position is supported by physician familiarity, multiple delivery formats, reimbursement precedent, and utility in patients with associated inflammatory bowel disease or uveitis.

Biosimilar competition is separating volume from revenue. NICE guidance covers adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab and extends recommendations to qualifying biosimilars, giving public purchasers a direct route to prioritize lower-cost alternatives.

AbbVie reported Q1 2026 Humira revenue of USD 688 million, down 38.6% year over year, while Rinvoq reached USD 2.119 billion, up 23.3% reported and 20.2% operationally. Across these two franchises, Rinvoq represented approximately 75.5% of their combined Q1 revenue, compared with Humira’s 24.5%, showing how value is moving away from the mature TNF-originator model.

UCB reported Cimzia revenue of EUR 1.954 billion in 2025, declining 4% even though volume grew approximately 4%. Net-price reductions more than offset prescription expansion. The result captures the central TNF market mechanism: the class can retain or increase patient share while generating weaker revenue per treatment year.

 

IL-17 Inhibitors Capture Premium Biologic Demand

IL-17 inhibitors are the principal premium biologic alternative to TNF therapy. Secukinumab and ixekizumab established the class, while bimekizumab introduced combined IL-17A and IL-17F inhibition. Competitive performance depends on response durability, prior therapy, psoriasis burden, inflammatory bowel disease considerations, administration preference, and payer placement.

The FDA expanded Bimzelx to active ankylosing spondylitis and active non-radiographic axial spondyloarthritis with objective inflammation in September 2024. This added a branded treatment option across both principal axial disease classifications and created another destination for treatment initiation and post-TNF switching.

UCB reported EUR 2.227 billion in 2025 Bimzelx sales and more than 116,000 treated patients across approved indications. Psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis together represented 19% of its indication mix, equivalent to approximately EUR 423 million of revenue across those three rheumatology indications. The axial contribution sits within that combined total, but the mix confirms meaningful monetization beyond dermatology.

Cosentyx remained the larger established IL-17 franchise, generating USD 1.566 billion in Q1 2026. Reported constant-currency sales declined 2%, although underlying global growth was approximately 2% after removing U.S. revenue-deduction effects. The contrast between Bimzelx’s rapid launch expansion and Cosentyx’s mature growth profile shows that IL-17 revenue is shifting toward intra-class competition rather than simple class creation.

 

Oral JAK Therapy Adds Convenience but Faces Sequencing Restrictions

JAK inhibitors create an oral, non-injectable targeted segment. Their administration advantage is commercially relevant, but U.S. Rinvoq labeling places active ankylosing spondylitis and objectively inflamed non-radiographic disease after inadequate response or intolerance to TNF blockers. This restricts first-line share while strengthening the product’s role in switching.

Rinvoq generated USD 8.304 billion globally in 2025, including USD 2.374 billion in the fourth quarter, when revenue increased 29.5%. Q1 2026 revenue reached USD 2.119 billion, up 23.3% reported. These franchise growth rates substantially exceed the 7.4% projected axial spondyloarthritis market CAGR, indicating that oral targeted therapies are gaining value within broader immunology portfolios even though axial-specific revenue is not separately reported.

Germany’s G-BA found that additional benefit for upadacitinib was not proven in the assessed non-radiographic groups because suitable comparative evidence against specified alternatives was unavailable. The decision demonstrates that regulatory access, market growth, and pricing power are separate commercial outcomes.

 

Reimbursement Separates Clinical Demand from Realized Revenue

Rheumatologists determine disease activity and treatment fit, but payers determine whether clinical demand becomes paid demand. Authorization commonly requires objective inflammation, previous therapy, specialist prescribing, preferred-product use, and documented response for continuation.

European reimbursement provides predictable access while exerting stronger price control. NICE recommendations cover established TNF inhibitors and eligible biosimilars, while switching to another TNF inhibitor is supported when the initial product is not tolerated, produces inadequate response, or loses efficacy. The mature TNF class therefore competes through procurement savings and formulary preference, whereas premium products must demonstrate sufficient clinical or administration value to justify higher net cost.

Targeted biologics’ estimated 68% market share gives payers a strong incentive to manage this segment aggressively. Even a modest reduction in net biologic price affects a much larger revenue pool than changes in conventional medication spending. Conversely, improved persistence or earlier biologic initiation can materially expand market value because each retained patient adds another recurring treatment year.

 

Persistence and Switching Determine Lifetime Patient Value

Switching is embedded in the market because patients may lose response, experience adverse effects, change insurance, or develop associated inflammatory conditions that favor another mechanism. The 54.4% 12-month persistence rate across U.S. targeted therapies shows that brand-level lifetime value is substantially lower than initiation data alone suggest.

The 2025 BSR guideline recognizes TNF, IL-17, and JAK pathways and recommends reassessment and switching when response is inadequate or lost. A second TNF inhibitor may remain appropriate, but movement to another mechanism can be commercially and clinically important after primary TNF failure.

Tapering can reduce dose intensity in sustained remission, although complete withdrawal produces high flare rates. Chronic continuation, renewal documentation, and successful switching therefore sustain class-level revenue even when individual brands lose patients. Manufacturers with stronger patient support, measurable outcomes, and payer-renewal execution can capture a larger share of the USD 3.79 billion targeted-biologic pool.

 

Pipeline Competition Is Concentrating Around Proven Pathways

Dual IL-17A/F inhibition has moved from pipeline development into commercial competition through bimekizumab. Future value will be created through long-term response, switching performance, reimbursement expansion, and persistence rather than first validation of the mechanism.

China is adding locally developed IL-17 competition. Akeso reported positive Phase III results for gumokimab in active ankylosing spondylitis, followed by Chinese regulatory acceptance of its new-drug application in January 2026. Successful approval and reimbursement could pressure imported biologics and widen regional access.

IL-23 inhibitors have not established a meaningful position in primary axial spondyloarthritis despite success in psoriasis and peripheral psoriatic arthritis. The 2025 BSR guideline specifically notes that IL-23p19 inhibitors used in psoriasis do not provide beneficial effects for axial symptoms. Near-term pipeline value is more likely to come from proven inflammatory pathways, selective oral agents, better sequencing, biomarkers, and stronger control of extra-musculoskeletal manifestations.

 

Regional Growth Reflects Different Access Models

The United States combines rapid specialist initiation, broad branded competition, high per-patient spending, and developed specialty-pharmacy infrastructure. Its commercial intensity is reflected in 47% biologic-containing first-line use in the specialist cohort and the 76.7% TNF share of index targeted therapies. Prior authorization, copay exposure, and fragmented formularies reduce conversion and persistence.

Europe offers clearer national reimbursement pathways but applies stronger health-technology assessment and price negotiation. England and Wales reimburse TNF products and qualifying biosimilars under defined criteria, while Germany demonstrates how an approved medicine can receive limited incremental-value recognition.

Asia-Pacific has an expanding diagnosed base but uneven reimbursement and specialist capacity. South Korean data showed age-standardized ankylosing spondylitis prevalence increasing from 34.6 to 91.0 per 100,000 between 2016 and 2023, while incidence rose from 4.41 to 8.33 per 100,000 person-years. China’s local biologic development can accelerate regional competition, while diagnostic delays and inconsistent coverage continue to restrict paid treatment in several markets.

 

Market Outlook

The axial spondyloarthritis market is shifting from a TNF-dominated structure toward a multi-class treatment environment. MRI-supported recognition of non-radiographic disease expands the patient funnel, IL-17 and JAK products create additional initiation and switching opportunities, and biosimilars reduce net revenue per patient in the mature TNF class.

Market revenue is projected to increase by USD 3.63 billion between 2025 and 2032. Under a stable 68% share, targeted biologics would contribute approximately USD 2.47 billion of that increase and reach USD 6.26 billion by 2032. TNF inhibitors will retain the largest utilization share, but IL-17 and oral JAK franchises are capturing a growing portion of premium revenue through differentiated mechanisms, delivery formats, and post-TNF switching.

Competitive advantage will favor companies that convert diagnosis into reimbursed initiation and then retain patients through measurable response, administration flexibility, support services, and payer renewal. Prevalence defines the theoretical ceiling; treatment share, net pricing, persistence, switching, and biologic CAGR determine realized market value.

 

Axial Spondyloarthritis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.58 Billion
Revenue Forecast in 2032	USD 9.21 Billion
Overall Growth Rate	CAGR of 7.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Type, By Route of Administration, By End User, By Distribution Channel, By Geography
By Treatment Type	TNF Inhibitors, IL-17 Inhibitors, JAK Inhibitors, NSAIDs, Conventional DMARDs, Other Therapies
By Disease Type	Radiographic Axial Spondyloarthritis, Non-Radiographic Axial Spondyloarthritis
By Route of Administration	Injectable, Oral, Intravenous
By End User	Hospitals, Rheumatology Clinics, Specialty Clinics, Homecare Settings
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of axial spondyloarthritis and autoimmune disorders Increasing adoption of biologic therapies and targeted immune-modulating treatments Growing awareness, improved diagnostic pathways, and expansion of rheumatology care infrastructure
Customization Option	Available upon request